【摘要】 目的分析恩替卡韦联合长效干扰素与短效干扰素治疗乙型肝炎e抗原(HBeAg)阳性慢性乙型肝炎的临床效果,为临床实践提供理论依据。方法 128例HBeAg阳性慢性乙型肝炎患者,以2011年2月～2014年2月收治的73例患者作为参照组,以2016年3月～2019年2月收治的55例患者作为研究组。参照组患者应用恩替卡韦联合短效干扰素治疗,研究组患者应用恩替卡韦联合长效干扰素治疗。对比两组治疗效果、HBeAg转阴率、乙型肝炎病毒的脱氧核糖核酸(HBV-DNA)转阴率、总胆红素及谷丙转氨酶水平。结果研究组治疗总有效率96.36%明显高于参照组的83.56%,差异有统计学意义(P<0.05)。治疗后,研究组总胆红素(25.56±12.62)μmol/L、谷丙转氨酶(35.72±11.47)U/L均低于参照组的(45.78±13.45)μmol/L、(69.61±12.53)U/L,差异有统计学意义(P<0.05)。研究组治疗后HBeAg转阴率、HBV-DNA转阴率均高于参照组,差异有统计学意义(P<0.05)。结论慢性乙型肝炎患者使用恩替卡韦联合长效干扰素治疗,有效消除临床症状,抑制乙型肝炎病毒,提高治疗有效率,改善肝功能,治疗效果显著,可广泛应用于临床。更多还原

【Abstract】 Objective To analyze the clinical effect of entecavir combined with long-acting interferon and short-acting interferon in the treatment of hepatitis B e antigen(HBeAg)-positive chronic hepatitis B, so as to provide theoretical basis for clinical practice. Methods Among 128 patients with HBeAg-positive chronic hepatitis B, 73 patients admitted from February 2011 to February 2014 were taken as the reference group, and 55 patients admitted from March 2016 to February 2019 were taken as the research group. The reference group was treated with entecavir combined with short-acting interferon, and the research group was treated with entecavir combined with long-acting interferon. The therapeutic effect, HBeAg negative-conversion rate, negative-conversion rate of hepatitis B virus deoxyribonucleic acid(HBV-DNA), total bilirubin and alanine aminotransferase level were compared between the two groups. Results The total effective rate 96.36% of the research group was obviously higher than 83.56% of the reference group, and the difference was statistically significant(P<0.05). After treatment, the total bilirubin(25.56±12.62) μmol/L and alanine aminotransferase(35.72±11.47) U/L of the research group were lower than(45.78±13.45) μmol/L and(69.61±12.53) U/L of the reference group, and the difference was statistically significant(P<0.05). After treatment, the negative-conversion rate of HBeAg and HBV-DNA of the research group were higher than those of the reference group, and the difference was statistically significant(P<0.05). Conclusion Combination of entecavir and long-term interferon shows remarkable therapeutic effect on patients with chronic hepatitis B, which can effectively eliminate clinical symptoms, inhibit hepatitis B virus, increase the effective rate of treatment, and improve liver function. It can be widely used in clinical practice.更多还原